Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

November 19, 2008

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB APPROVAL			
							OMB Number:	3235-0287		
ar .							Expires:	January 31		
Section 16. Form 4 or							Estimated average burden hours per response 0.5			
nue. Section 17(a		· ·	_	_			on			
esponses)										
1. Name and Address of Reporting Person ** Graves Kurt			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	INC	/ MA [VRT]	X]			(Che	ск ан аррисаон	z)		
(Last) (First) (Middle) C/O VERTEX			3. Date of Earliest Transaction (Month/Day/Year) 11/18/2008				below)			
	/ERLY									
						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
E, MA 02139						Form filed by I Person	More than One Re	eporting		
(State) (2	Zip)	Гable I - Non-D	erivative S	Securi	ities Acc	quired, Disposed o	f, or Beneficial	lly Owned		
(Month/Day/Year) Execution any		on Date, if Transaction Code		spose 4 and (A)	d of	Securities Beneficially Owned Following Reported Transaction(s)	(D) or			
		Code V	Amount	(D)	Price \$	(Instr. 3 and 4)				
11/18/2008		S <u>(1)</u>	379	D	26.1 (2) (3)	56,164	D			
						250	I	401(k)		
	Filed purs Section 17(a serion	Filed pursuant to Section Section 17(a) of the Publication 30(h) of the Section 30(h) of the	Washington, s box Filed pursuant to Section 16(a) of the Section 17(a) of the Public Utility Hold 30(h) of the Investment Seponses Address of Reporting Person 2. Issuer Name and Symbol VERTEX PHAR INC / MA [VRT2] (First) (Middle) 3. Date of Earliest Tr (Month/Day/Year) X 11/18/2008 EUTICALS ATED, 130 WAVERLY (Street) 4. If Amendment, Da Filed(Month/Day/Year) GE, MA 02139 (State) (Zip) Table I - Non-D 2. Transaction Date 2A. Deemed 3. (Month/Day/Year) 2. Transaction Date 2A. Deemed 3. (Month/Day/Year) Execution Date, if Transaction any Code (Month/Day/Year) (Instr. 8)	Washington, D.C. 20: STATEMENT OF CHANGES IN BENEFI SECURITIES Filed pursuant to Section 16(a) of the Securities Section 17(a) of the Public Utility Holding Company Section 30(h) of the Investment Company Symbol VERTEX PHARMACEUTINC / MA [VRTX] (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) X 11/18/2008 EUTICALS ATED, 130 WAVERLY (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) GE, MA 02139 (State) (Zip) Table I - Non-Derivative State (Month/Day/Year) 2. Transaction Date 2A. Deemed 3. 4. Security (Month/Day/Year) Execution Date, if Transaction(A) or Diany Code (D) (Month/Day/Year) (Instr. 8) (Instr. 3, Code V Amount)	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIA SECURITIES Filed pursuant to Section 16(a) of the Securities E. Section 17(a) of the Public Utility Holding Company 30(h) of the Investment Company Action Seponses Iddress of Reporting Person * 2. Issuer Name and Ticker or Tradir Symbol VERTEX PHARMACEUTICA INC / MA [VRTX] (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) X 11/18/2008 EUTICALS ATED, 130 WAVERLY (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) GE, MA 02139 (State) (Zip) Table I - Non-Derivative Securities A (Month/Day/Year) Execution Date, if Transaction(A) or Dispose any Code (D) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and or Code V Amount (D)	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OW SECURITIES Filed pursuant to Section 16(a) of the Securities Exchanges Section 17(a) of the Public Utility Holding Company Act of 194 (a) of the Investment Company Act of 195 (b) of the Investment Company Act of 195 (b) of the Investment Company Act of 195 (c) (b) of the Investment Company Act of 195 (c) (c) (d) of the Investment Company Act of 195 (c) (d) of the Investment Company Act of 195 (c) (d) of the Investment Company Act of 195 (c) (e) (e) (e) (e) (e) (e) (e) (e) (e) (e	Washington, D.C. 20549 Error STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, some and the section 30(h) of the Investment Company Act of 1940 Esponses) Iddress of Reporting Person 2 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 11/18/2008 EUTICALS ATED, 130 WAVERLY (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) Applicable Line) X. Form filed by Person (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of Code (D) (Month/Day/Year) (Instr. 3, 4 and 5) Owned Following Reported Transaction(s) (Instr. 3 and 4) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Following Reported Transaction(s) (Instr. 3 and 4) (Instr. 3 and 4) Sall Sall Sall Sall Sall Sall Sall Sal	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Seponses) Idress of Reporting Person 2 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) I1/18/2008 SUTICALS ATED, 130 WAVERLY (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) SEE, MA 02139 (State) (Zip) Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially (Month/Day/Year) Secution Date, if Transaction/A) or Disposed of any (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 4) Reported Transaction(s) (Instr. 4) Reported Transaction(s) (Instr. 3) and 4) 11/18/2008 SEI) 379 D 26.1 56,164 D		

Persons who respond to the collection of information contained in this form are not

required to respond unless the form

SEC 1474 (9-02)

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2.	3. Transaction Date (Month/Day/Year)		4.	5. onNumber	6. Date Exerc		7. Titl		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	(Month/Day/Tear)	any (Month/Day/Year)	Code (Instr. 8)	of			Under Secur	rlying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Graves Kurt C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139

EVP, Chief Commercial Officer

Signatures

Valerie L. Andrews, Attorney-In-Fact

11/19/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a wieghted average price of \$26.10 (range \$25.75 to \$26.53).
- (3) Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2